Hsbc Holdings PLC cut its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 9.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 47,563 shares of the biotechnology company’s stock after selling 4,980 shares during the period. Hsbc Holdings PLC owned 0.11% of United Therapeutics worth $6,082,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in UTHR. United Services Automobile Association lifted its stake in United Therapeutics by 8.0% during the third quarter. United Services Automobile Association now owns 61,853 shares of the biotechnology company’s stock worth $7,910,000 after purchasing an additional 4,604 shares in the last quarter. Standard Life Aberdeen plc raised its stake in shares of United Therapeutics by 55.9% in the third quarter. Standard Life Aberdeen plc now owns 44,754 shares of the biotechnology company’s stock valued at $5,723,000 after acquiring an additional 16,039 shares in the last quarter. Franklin Resources Inc. raised its stake in shares of United Therapeutics by 16.1% in the third quarter. Franklin Resources Inc. now owns 16,512 shares of the biotechnology company’s stock valued at $2,111,000 after acquiring an additional 2,293 shares in the last quarter. AMP Capital Investors Ltd raised its stake in shares of United Therapeutics by 8.6% in the third quarter. AMP Capital Investors Ltd now owns 62,465 shares of the biotechnology company’s stock valued at $7,894,000 after acquiring an additional 4,931 shares in the last quarter. Finally, Baird Financial Group Inc. raised its stake in shares of United Therapeutics by 2.1% in the third quarter. Baird Financial Group Inc. now owns 35,162 shares of the biotechnology company’s stock valued at $4,429,000 after acquiring an additional 728 shares in the last quarter. Hedge funds and other institutional investors own 97.24% of the company’s stock.
Several analysts have recently issued reports on the company. BidaskClub cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Oppenheimer set a $160.00 price objective on United Therapeutics and gave the company a “buy” rating in a research note on Tuesday, November 20th. Credit Suisse Group increased their price objective on United Therapeutics from $103.00 to $105.00 and gave the company a “sell” rating in a research note on Monday, November 19th. Cowen set a $106.00 price objective on United Therapeutics and gave the company a “hold” rating in a research note on Thursday, November 15th. Finally, JPMorgan Chase & Co. increased their price objective on United Therapeutics from $118.00 to $126.00 and gave the company a “neutral” rating in a research note on Friday, November 2nd. Two analysts have rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $134.00.
Shares of NASDAQ UTHR opened at $109.44 on Friday. The firm has a market capitalization of $4.94 billion, a PE ratio of 10.05, a P/E/G ratio of 26.44 and a beta of 1.24. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.05 and a current ratio of 4.32. United Therapeutics Co. has a 12-month low of $100.57 and a 12-month high of $152.55.
United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 31st. The biotechnology company reported $2.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.23 by ($0.81). The company had revenue of $412.70 million during the quarter, compared to analyst estimates of $378.22 million. United Therapeutics had a net margin of 31.73% and a return on equity of 25.24%. The firm’s revenue was down 7.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $4.69 earnings per share. As a group, analysts anticipate that United Therapeutics Co. will post 14.28 earnings per share for the current year.
In related news, Director Christopher Causey sold 810 shares of the stock in a transaction on Monday, September 10th. The stock was sold at an average price of $119.00, for a total value of $96,390.00. Following the transaction, the director now owns 1,555 shares of the company’s stock, valued at $185,045. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 8.20% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2018/12/08/united-therapeutics-co-uthr-position-reduced-by-hsbc-holdings-plc.html.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
See Also: Earnings Reports
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.